Wegovy, the semaglutide-based weight loss medication, has become a pivotal choice for people in the UK seeking medical support for obesity, especially following the recent price increases for alternatives like Mounjaro. As many turn to private providers amid NHS delays and strict eligibility, understanding current pricing, access pathways, and the benefits of different pharmacy options has never been more vital.
Wegovy Price Trends in 2025
The UK has seen notable changes in weight loss medication markets in 2025, mainly driven by significant Mounjaro price hikes in September. While Mounjaro now costs as much as £384 for the highest dose, Wegovy prices have remained comparatively stable across most private providers. Typical costs for Wegovy pens in leading high-street and online pharmacies are as follows:
- 0.25mg/0.5mg/1mg starter pens: Approximately £103–£118 per pen
- 1.7mg pens: Around £175–£178 per pen
- 2.4mg highest dose: About £188–£245 per pen, depending on the provider
As cost pressures rise, a key shift has occurred: Wegovy, formerly only marginally less expensive than Mounjaro, is now consistently the more affordable and accessible choice among the two, especially for private patients who do not meet strict NHS criteria.
SheMed’s £89 Wegovy Offer: Best in the Market
Among all UK online clinics and high street pharmacies, SheMed stands out with a compelling offer: Wegovy for just £89 in the first month, including a starter package with blood test and tailored support. Compared to prices that start at £103-£189 at other providers, this marks the most affordable entry point for anyone starting Wegovy in the UK market as of October 2025.
The offer extends beyond just a low initial price. After the introductory month, SheMed’s ongoing fee is a transparent £159 per month, with no hidden surcharges for higher doses as patients progress in their weight loss journey. This predictability allows for easier financial planning and sets SheMed apart from other pharmacies that charge up to £245 for the highest Wegovy strength.
Comparing SheMed to Other Pharmacies
While pharmacy pricing fluctuates based on supply, prescription costs, and clinical support packages, SheMed’s model brings both affordability and reliability. A brief comparison:
| Provider | First Month Price | Ongoing Monthly Price | Highest Dose Price | Hidden Fees | Support Package |
| SheMed | £89 | £159 | £159 | None | Blood test + 24/7 care |
| Large Online Clinics | £103-£130 | £145-£215 | £175-£245 | Sometimes | Standard (varies) |
| High Street Pharmacies | £118-£189 | £148-£245 | £178-£245 | Sometimes | Standard |
This table shows that SheMed’s introductory rate is at least £30–£60 lower than competitors, with the added value of a blood test and continuous side-effect care at no extra cost. Moreover, SheMed’s prices stay the same even as patients escalate dosing, a common scenario where costs rise rapidly at other pharmacies.
Wegovy Availability on the NHS: Opportunities and Delays
While Wegovy is technically available on the NHS for weight management, the reality for most candidates involves long wait times and strict eligibility. NHS approval is based on National Institute for Health and Care Excellence (NICE) guidelines, requiring:
- BMI of 35+ with at least one weight-related health condition (e.g., diabetes, hypertension)
- Referral to a specialist weight management service not a direct GP prescription
- Evidence of failed attempts with diet and lifestyle therapies
It’s common for waitlists to stretch many months or even longer, especially in regions where specialist services are overburdened. There is also an upper cap on the number of prescriptions that NHS weight management teams can issue due to funding allocations and supply constraints.
For those who do not precisely meet NHS cutoffs, or simply seek a swifter, less bureaucratic route, private providers have rapidly become the go-to option. Private access involves an online or in-person clinical assessment and, if appropriate, a prescription filled directly by the pharmacy, without referral backlogs.
Why Private Access (and SheMed) Makes Sense
Given the unpredictability of NHS waiting times and strict eligibility criteria for Wegovy private provision stands out for several reasons:
- Speed: Most private clinics offer same-week consultation and prescription, allowing patients to begin treatment promptly.
- Wider Eligibility: Private pharmacies accept a broader range of BMI and comorbidity profiles than the NHS, offering treatment to more people who would otherwise be excluded from medical support.
- Ongoing Medical Support: Reputable private providers, including SheMed, include regular progress reviews, support for side effects, and prescription adjustments, often with a dedicated clinical team available online.
While NHS access is ideal for those who qualify and have the patience to endure waiting lists, private access especially at competitive prices offers a viable, reliable alternative for immediate support, enabling more people to benefit from proven GLP-1 therapies.
The Impact of Price Changes on UK Patients
Recent increases in Mounjaro’s price have exacerbated the cost gap between weight loss medications. With Mounjaro now charging up to £384 per dose for the highest strength and Wegovy remaining stable, patients especially those funding their own treatment can make significant savings by moving to Wegovy, particularly via a low-cost provider such as SheMed.
Furthermore, price security beyond the first month means patients don’t face unwelcome surprises as their prescribed dose escalates, a common scenario in weight-loss programmes aiming for sustained results.
Key Points for UK Consumers
- Wegovy is now the best-value weight loss medication in the UK market, especially after Mounjaro price hikes.
- Private access to Wegovy is fast, flexible, and more inclusive than the NHS route, though it comes at a monthly cost.
- SheMed’s £89 introductory offer leads the market for value and reliability, with straightforward ongoing pricing and robust patient care included.
- The NHS remains a vital route for those who qualify and can wait, but for many patients, SheMed and similar clinics offer a much quicker, easier, and more predictable path to effective medical weight management.
While consideration of eligibility, safety, and clinical oversight remains crucial for all weight loss medications, savvy UK consumers in 2025 will find Wegovy (especially through SheMed’s £89 deal) to deliver the best balance of price, reliability, and support across both NHS and private health landscapes.
